Navigation Links
Bright Light Therapy via Ear Canals Improved Reaction Times of Top Athletes in a Placebo-Controlled Psycho-Motoric Study
Date:12/14/2011

HELSINKI, December 14, 2011 /PRNewswire/ --

A placebo controlled study involving top ice hockey players from the Finnish national league has shown motoric reaction times reduced by one fifth in players using the Valkee bright light headset. In the treatment group, the athletes were given 12 minutes of bright light via the ear canal each morning for three weeks. The study was conducted by the Department of Exercise and Medical Physiology at Verve Research, Finland.

Motoric reaction times describe how quickly we react to visual stimulus and convert these into actual movements. The Valkee bright light headset is a portable device that channels 8-12 minute doses of safe bright light directly to light-sensitive areas of the brain via the ear canal. Earlier in 2011, University of Oulu, Finland, presented two clinical trials using bright light via ear canals to treat seasonal affective disorder, and the presence of light-sensitive cells in the human brain.

Docent Mikko Tulppo, who led the study at the Department of Exercise and Medical Physiology at Verve Research, Finland, commented: "The placebo-controlled study showed a significant improvement in motoric reaction times of top athletes using bright light via the ear canal."  

Juuso Nissilä, chief scientist at Valkee, the inventor of the bright light headset, said: "The ice hockey players were all in prime cognitive and physical condition, and their reaction times were already extremely fast already before using the Valkee bright light headset. The fact that bright light via ear canals is proving to provide an additional edge is very promising for athletes and sports enthusiasts."

This placebo-controlled, phycho-motoric study of Valkee bright light via ear canal on national level ice hockey players in Finland was conducted independently by the Department of Exercise and Medical Physiology at Verve Research in the fall 2011.

Valkee launched its bright-light headset in August 2010. Being based on cross-functional science in neurology, biology, psychiatry and physiology, Valkee is a CE-certified Class II(a) medical device under the EU regulations.


About Valkee

The Valkee (http://valkee.com) bright light headset channels bright light direct to light-sensitive areas of the human brain via ear canals to improve mood and performance. In earlier clinical trials, 9 of 10 patients suffering from severe seasonal affective disorder - also known as winter blues - experienced total symptom relief latest in 4 weeks with a daily 8-12 minute dose. Valkee is based on scientific research carried out since 2007, and is a CE-marked Class II(a) medical device. More information and for international online shop http://valkee.com

About Department of Exercise and Medical Physiology at Verve

Verve is a Finnish nationwide provider of research, rehabilitation and consulting services for occupational health, and physiology and exercise research. The Department of Exercise and Medical Physiology at verve engages in cross-disciplinary research, which most significantly integrates exercise physiology, cardiology and mathematics. Verve's research team is especially interested in the interrelationships of cardiac function, exercise, stress and cognitive performance.



'/>"/>
SOURCE Valkee
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Waterproof Keyboard Now Has Brighter, More Efficient Backlighting
2. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
3. Solta Medical Receives Provectus Innovation Award at MDB Capital Groups Bright Lights Intellectual Property Conference
4. An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety
5. 2011 China-Africa Brightness Action Launched in Beijing
6. Sanare Launches BrightSky, a New Consumer Brand Serving People Living With Diabetes
7. Sanare and BrightSky Announce National Strategic Partnership with American Diabetes Association
8. NewCardio to Showcase Cardiac Diagnostic Technology at MDB Capitals Bright Lights Conference in New York City on May 10, 2011
9. Misonix to Present at the MDB Capital Bright Lights Conference on May 11, 2011
10. BrightLife Direct Introduces 3 New Lymphedema Product Lines
11. Alexza to Present at the MDB Bright Lights Conference 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... , media relations, content marketing, social media management, corporate communications, SEO and cause ... the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus ...
(Date:2/23/2017)... Colorado (PRWEB) , ... February 23, 2017 , ... ... Magazine, an exciting, new, interactive publication where generations converge and explore the world ... expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... York (PRWEB) , ... February 22, 2017 , ... ... entrance and lobby of a new healthcare contact center in Georgia, PENETRON Specialty ... One of the nation’s largest healthcare systems recently invested $51 million to purchase ...
Breaking Medicine News(10 mins):